drugset / Trial / NCT04755543
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
Non-randomizedParallel-groupOpen-labelTreatment
Summary
LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety, pharmacokinetics and preliminary efficacy of LP002 for the treatment of malignant digestive system neoplasms will be evaluated.
Timeline
- Start
- 2019-06-17
- Primary completion
- 2021-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP002 | Monoclonal antibody | 600 mg | Intravenous |
| Subject | LP002 | Monoclonal antibody | 900 mg | Intravenous |
| Subject | OH2 | Other / unclassified | 106 unknown | Other |
| Subject | OH2 | Other / unclassified | 107 unknown | Other |
| Subject | OH2 | Other / unclassified | 108 unknown | Other |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2000 mg/m2 | Intravenous |